Inflammatory targets of therapy in sickle cell disease

Translational Research

Volumn 167, Issue 1, 2016, Pages 281-297

  Owusu Ansah, Amma ^a,b   Ihunnah, Chibueze A ^a,b   Walker, Aisha L ^a,b   Ofori Acquah, Solomon F ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ANTIINFLAMMATORY AGENT; C REACTIVE PROTEIN; CALPHOSTIN C; DEXAMETHASONE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GLUTATHIONE; HAPTOGLOBIN; HEMIN; HEMOGLOBIN A; HEMOGLOBIN S; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYUREA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLAMMASOME; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 1BETA CONVERTING ENZYME; INTERLEUKIN 6; INTERLEUKIN 8; LEVACECARNINE; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; OPIATE; RESATORVID; SALAZOSULFAPYRIDINE; THIOCTIC ACID; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ACUTE CHEST SYNDROME; CLINICAL FEATURE; CROHN DISEASE; ENDOTHELIAL DYSFUNCTION; HUMAN; HYPERALGESIA; INFLAMMATION; INNATE IMMUNITY; INTRAVASCULAR HEMOLYSIS; MAST CELL; MOLECULAR MECHANICS; MULTIPLE ORGAN FAILURE; NONHUMAN; PATHOGENESIS; PATHOLOGY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SICKLE CELL ANEMIA; SIGNAL TRANSDUCTION; ANEMIA, SICKLE CELL; ANIMAL; COMPLICATION;

ANEMIA, SICKLE CELL; ANIMALS; ANTI-INFLAMMATORY AGENTS; HUMANS; HYDROXYUREA; INFLAMMATION; SIGNAL TRANSDUCTION;

EID: 84952637592     PISSN: 19315244     EISSN: 18781810     Source Type: Journal    
DOI: 10.1016/j.trsl.2015.07.001     Document Type: Review

References (209)

1. S. Embury, R.P. Hebbel, N. Mohandas, and M.H. Steinberg Sickle cell disease: basic principles and clinical practice 1995 Raven Press New York
2. J.D. Belcher, H. Mahaseth, T.E. Welch, and et al. Critical role of endothelial cell activation in hypoxia-induced vasoocclusion in transgenic sickle mice Am J Physiol Heart Circ Physiol 288 2005 H2715 H2725
3. H. Mahaseth, G.M. Vercellotti, T.E. Welch, and et al. Polynitroxyl albumin inhibits inflammation and vasoocclusion in transgenic sickle mice J Lab Clin Med 145 2005 204 211
4. D.K. Kaul, X.D. Liu, S. Choong, J.D. Belcher, G.M. Vercellotti, and R.P. Hebbel Anti-inflammatory therapy ameliorates leukocyte adhesion and microvascular flow abnormalities in transgenic sickle mice Am J Physiol Heart Circ Physiol 287 2004 H293 H301
5. B.N. Setty, and M.J. Stuart Vascular cell adhesion molecule-1 is involved in mediating hypoxia-induced sickle red blood cell adherence to endothelium: potential role in sickle cell disease Blood 88 1996 2311 2320
6. S.H. Embury, N.M. Matsui, S. Ramanujam, and et al. The contribution of endothelial cell P-selectin to the microvascular flow of mouse sickle erythrocytes in vivo Blood 104 2004 3378 3385
7. J.D. Belcher, C.J. Bryant, J. Nguyen, and et al. Transgenic sickle mice have vascular inflammation Blood 101 2003 3953 3959
8. S.C. Taylor, S.J. Shacks, R.A. Mitchell, and A. Banks Serum interleukin-6 levels in the steady state of sickle cell disease J Interferon Cytokine Res 15 1995 1061 1064
9. R.B. Francis Jr., and L.J. Haywood Elevated immunoreactive tumor necrosis factor and interleukin-1 in sickle cell disease J Natl Med Assoc 84 1992 611 615
10. A.J. Duits, J.B. Schnog, L.R. Lard, A.W. Saleh, and R.A. Rojer Elevated IL-8 levels during sickle cell crisis Eur J Haematol 61 1998 302 305
11. O.S. Platt, D.J. Brambilla, W.F. Rosse, and et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death N Engl J Med 330 1994 1639 1644
12. O. Castro, D.J. Brambilla, B. Thorington, and et al. The acute chest syndrome in sickle cell disease: incidence and risk factors. The Cooperative Study of Sickle Cell Disease Blood 84 1994 643 649
13. M.T. Gladwin, and E. Vichinsky Pulmonary complications of sickle cell disease N Engl J Med 359 2008 2254 2265
14. E.P. Vichinsky, L.D. Neumayr, A.N. Earles, and et al. Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group N Engl J Med 342 2000 1855 1865
15. B. Maitre, A. Habibi, F. Roudot-Thoraval, and et al. Acute chest syndrome in adults with sickle cell disease Chest 117 2000 1386 1392
16. C. Andreotti, A.A. King, E. Macy, B.E. Compas, and M.R. DeBaun The Association of Cytokine Levels With Cognitive Function in Children With Sickle Cell Disease and Normal MRI Studies of the Brain J Child Neurol 30 2015 1349 1353
17. F.A. Wagener, A. Eggert, O.C. Boerman, and et al. Heme is a potent inducer of inflammation in mice and is counteracted by heme oxygenase Blood 98 2001 1802 1811
18. M. Foidart, H.H. Liem, B.T. Adornato, W.K. Engel, and U. Muller-Eberhard Hemopexin metabolism in patients with altered serum levels J Lab Clin Med 102 1983 838 846
19. U. Muller-Eberhard, J. Javid, H.H. Liem, A. Hanstein, and M. Hanna Plasma concentrations of hemopexin, haptoglobin and heme in patients with various hemolytic diseases Blood 32 1968 811 815
20. C.D. Reiter, X. Wang, J.E. Tanus-Santos, and et al. Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease Nat Med 8 2002 1383 1389
21. T.A. Bensinger, and P.N. Gillette Hemolysis in sickle cell disease Arch Intern Med 133 1974 624 631
22. R.P. Rother, L. Bell, P. Hillmen, and M.T. Gladwin The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease JAMA 293 2005 1653 1662
23. M.T. Gladwin, and S.F. Ofori-Acquah Erythroid DAMPs drive inflammation in SCD Blood 123 2014 3689 3690
24. T.L. Mollan, and A.I. Alayash Redox reactions of hemoglobin: mechanisms of toxicity and control Antioxid Redox Signal 18 2013 2251 2253
25. M.S. Hargrove, T. Whitaker, J.S. Olson, R.J. Vali, and A.J. Mathews Quaternary structure regulates hemin dissociation from human hemoglobin J Biol Chem 272 1997 17385 17389
26. K. Sheng, M. Shariff, and R.P. Hebbel Comparative oxidation of hemoglobins A and S Blood 91 1998 3467 3470
27. F.A. Kuypers Hemoglobin s polymerization and red cell membrane changes Hematol Oncol Clin North Am 28 2014 155 179
28. M. Stefanovic, E. Puchulu-Campanella, G. Kodippili, and P.S. Low Oxygen regulates the band 3-ankyrin bridge in the human erythrocyte membrane Biochem J 449 2013 143 150
29. A. Jeffers, M.T. Gladwin, and D.B. Kim-Shapiro Computation of plasma hemoglobin nitric oxide scavenging in hemolytic anemias Free Radic Biol Med 41 2006 1557 1565
30. F. Vinchi, and E. Tolosano Therapeutic approaches to limit hemolysis-driven endothelial dysfunction: scavenging free heme to preserve vasculature homeostasis Oxid Med Cell Longev 2013 2013 396527
31. L. Zhang, A. Levy, and J.M. Rifkind Autoxidation of hemoglobin enhanced by dissociation into dimers J Biol Chem 266 1991 24698 24701
32. R.E. Benesch, and S. Kwong The stability of the heme-globin linkage in some normal, mutant, and chemically modified hemoglobins J Biol Chem 265 1990 14881 14885
33. J.D. Belcher, H. Mahaseth, T.E. Welch, L.E. Otterbein, R.P. Hebbel, and G.M. Vercellotti Heme oxygenase-1 is a modulator of inflammation and vaso-occlusion in transgenic sickle mice J Clin Invest 116 2006 808 816
34. S. Ghosh, and S.F. Ofori-Acquah Acute chest syndrome in transgenic mouse models of sickle cell disease triggered by free heme Blood 116 suppl 1 2010 944
35. S. Ghosh, O.A. Adisa, P. Chappa, and et al. Extracellular hemin crisis triggers acute chest syndrome in sickle mice J Clin Invest 123 2013 4809 4820
36. C.J. Bean, S.L. Boulet, D. Ellingsen, and et al. Heme oxygenase-1 gene promoter polymorphism is associated with reduced incidence of acute chest syndrome among children with sickle cell disease Blood 120 2012 3822 3828
37. G. Galarneau, S. Coady, M.E. Garrett, and et al. Gene-centric association study of acute chest syndrome and painful crisis in sickle cell disease patients Blood 122 2013 434 442
38. J.D. Belcher, C. Chen, J. Nguyen, and et al. Heme triggers TLR4 signaling leading to endothelial cell activation and vaso-occlusion in murine sickle cell disease Blood 123 2014 377 390
39. V. Brinkmann, U. Reichard, C. Goosmann, and et al. Neutrophil extracellular traps kill bacteria Science 303 2004 1532 1535
40. G. Chen, D. Zhang, T.A. Fuchs, D. Manwani, D.D. Wagner, and P.S. Frenette Heme-induced neutrophil extracellular traps contribute to the pathogenesis of sickle cell disease Blood 123 2014 3818 3827
41. F. Vinchi, L. De Franceschi, A. Ghigo, and et al. Hemopexin therapy improves cardiovascular function by preventing heme-induced endothelial toxicity in mouse models of hemolytic diseases Circulation 127 2013 1317 1329
42. X. Liang, T. Lin, G. Sun, L. Beasley-Topliffe, J.M. Cavaillon, and H.S. Warren Hemopexin down-regulates LPS-induced proinflammatory cytokines from macrophages J Leukoc Biol 86 2009 229 235
43. T. Lin, Y.H. Kwak, F. Sammy, and et al. Synergistic inflammation is induced by blood degradation products with microbial Toll-like receptor agonists and is blocked by hemopexin J Infect Dis 202 2010 624 632
44. H. Hada, T. Shiraki, M. Watanabe-Matsui, and K. Igarashi Hemopexin-dependent heme uptake via endocytosis regulates the Bach1 transcription repressor and heme oxygenase gene activation Biochim Biophys Acta 1840 2014 2351 2360
45. W.W. Bakker, T. Borghuis, M.C. Harmsen, and et al. Protease activity of plasma hemopexin Kidney Int 68 2005 603 610
46. D.J. Schaer, and P.W. Buehler Cell-free hemoglobin and its scavenger proteins: new disease models leading the way to targeted therapies Cold Spring Harb Perspect Med 3 2013
47. T.W. Rice, A.P. Wheeler, G.R. Bernard, and et al. A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis Crit Care Med 38 2010 1685 1694
48. B.J. Wu, K. Chen, P.J. Barter, and K.A. Rye Niacin inhibits vascular inflammation via the induction of heme oxygenase-1 Circulation 125 2012 150 158
49. H.M. Scoffone, M. Krajewski, S. Zorca, and et al. Effect of extended-release niacin on serum lipids and on endothelial function in adults with sickle cell anemia and low high-density lipoprotein cholesterol levels Am J Cardiol 112 2013 1499 1504
50. T. Strowig, J. Henao-Mejia, E. Elinav, and R. Flavell Inflammasomes in health and disease Nature 481 2012 278 286
51. K. Schroder, and J. Tschopp The inflammasomes Cell 140 2010 821 832
52. B.K. Davis, H. Wen, and J.P. Ting The inflammasome NLRs in immunity, inflammation, and associated diseases Annu Rev Immunol 29 2011 707 735
53. B.A. Cerqueira, W.V. Boas, A.D. Zanette, M.G. Reis, and M.S. Goncalves Increased concentrations of IL-18 and uric acid in sickle cell anemia: contribution of hemolysis, endothelial activation and the inflammasome Cytokine 56 2011 471 476
54. A.D. Greenhalgh, D. Brough, E.M. Robinson, S. Girard, N.J. Rothwell, and S.M. Allan Interleukin-1 receptor antagonist is beneficial after subarachnoid haemorrhage in rat by blocking haem-driven inflammatory pathology Dis Model Mech 5 2012 823 833
55. M.R. de Zoete, N.W. Palm, S. Zhu, and R.A. Flavell Inflammasomes Cold Spring Harb Perspect Biol 6 2014 a016287
56. J.P. Ting, R.C. Lovering, E.S. Alnemri, and et al. The NLR gene family: a standard nomenclature Immunity 28 2008 285 287
57. E. Latz, T.S. Xiao, and A. Stutz Activation and regulation of the inflammasomes Nat Rev Immunol 13 2013 397 411
58. F.F. Dutra, L.S. Alves, D. Rodrigues, and et al. Hemolysis-induced lethality involves inflammasome activation by heme Proc Natl Acad Sci U S A 111 2014 E4110 E4118
59. R.C. Coll, A.A. Robertson, J.J. Chae, and et al. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases Nat Med 21 2015 248 255
60. S. Schilling, S. Goelz, R. Linker, F. Luehder, and R. Gold Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration Clin Exp Immunol 145 2006 101 107
61. G. Lopez-Castejon, and P. Pelegrin Current status of inflammasome blockers as anti-inflammatory drugs Expert Opin Investig Drugs 21 2012 995 1007
62. K.A. Boost, S. Hoegl, C. Hofstetter, and et al. Targeting caspase-1 by inhalation-therapy: effects of Ac-YVAD-CHO on IL-1 beta, IL-18 and downstream proinflammatory parameters as detected in rat endotoxaemia Intensive Care Med 33 2007 863 871
63. E. Feist, and G.R. Burmester Canakinumab for treatment of cryopyrin-associated periodic syndrome Expert Opin Biol Ther 10 2010 1631 1636
64. N. Arulkumaran, R.J. Unwin, and F.W. Tam A potential therapeutic role for P2X7 receptor (P2X7R) antagonists in the treatment of inflammatory diseases Expert Opin Investig Drugs 20 2011 897 915
65. S.C. Sun The noncanonical NF-kappaB pathway Immunol Rev 246 2012 125 140
66. M.S. Hayden, and S. Ghosh NF-kappaB in immunobiology Cell Res 21 2011 223 244
67. M.S. Hayden, and S. Ghosh Regulation of NF-kappaB by TNF family cytokines Semin Immunol 26 2014 253 266
68. M.S. Hayden, and S. Ghosh Shared principles in NF-kappaB signaling Cell 132 2008 344 362
69. V.F. Shih, R. Tsui, A. Caldwell, and A. Hoffmann A single NFkappaB system for both canonical and non-canonical signaling Cell Res 21 2011 86 102
70. R. Kollander, A. Solovey, L.C. Milbauer, F. Abdulla, R.J. Kelm Jr., and R.P. Hebbel Nuclear factor-kappa B (NFkappaB) component p50 in blood mononuclear cells regulates endothelial tissue factor expression in sickle transgenic mice: implications for the coagulopathy of sickle cell disease Transl Res 155 2010 170 177
71. J.I. Lee, and G.J. Burckart Nuclear factor kappa B: important transcription factor and therapeutic target J Clin Pharmacol 38 1998 981 993
72. P.P. Tak, and G.S. Firestein NF-kappaB: a key role in inflammatory diseases J Clin Invest 107 2001 7 11
73. C. Stevens, M. Lipman, S. Fabry, and et al. 5-Aminosalicylic acid abrogates T-cell proliferation by blocking interleukin-2 production in peripheral blood mononuclear cells J Pharmacol Exp Ther 272 1995 399 406
74. A.A. Solovey, A.N. Solovey, J. Harkness, and R.P. Hebbel Modulation of endothelial cell activation in sickle cell disease: a pilot study Blood 97 2001 1937 1941
75. K. De Bosscher, W. Vanden Berghe, and G. Haegeman The interplay between the glucocorticoid receptor and nuclear factor-kappaB or activator protein-1: molecular mechanisms for gene repression Endocr Rev 24 2003 488 522
76. K. De Bosscher, W. Vanden Berghe, L. Vermeulen, S. Plaisance, E. Boone, and G. Haegeman Glucocorticoids repress NF-kappaB-driven genes by disturbing the interaction of p65 with the basal transcription machinery, irrespective of coactivator levels in the cell Proc Natl Acad Sci U S A 97 2000 3919 3924
77. L.I. McKay, and J.A. Cidlowski Cross-talk between nuclear factor-kappa B and the steroid hormone receptors: mechanisms of mutual antagonism Mol Endocrinol 12 1998 45 56
78. F. Vallelian, C.A. Schaer, T. Kaempfer, and et al. Glucocorticoid treatment skews human monocyte differentiation into a hemoglobin-clearance phenotype with enhanced heme-iron recycling and antioxidant capacity Blood 116 2010 5347 5356
79. T.C. Griffin, D. McIntire, and G.R. Buchanan High-dose intravenous methylprednisolone therapy for pain in children and adolescents with sickle cell disease N Engl J Med 330 1994 733 737
80. F. Ogunlesi, M.M. Heeney, and A.C. Koumbourlis Systemic corticosteroids in acute chest syndrome: friend or foe? Paediatr Respir Rev 15 2014 24 27
81. J.C. Bernini, Z.R. Rogers, E.S. Sandler, J.S. Reisch, C.T. Quinn, and G.R. Buchanan Beneficial effect of intravenous dexamethasone in children with mild to moderately severe acute chest syndrome complicating sickle cell disease Blood 92 1998 3082 3089
82. C.T. Quinn, M.J. Stuart, K. Kesler, and et al. Tapered oral dexamethasone for the acute chest syndrome of sickle cell disease Br J Haematol 155 2011 263 267
83. R. Lee, P. Beauparlant, H. Elford, P. Ponka, and J. Hiscott Selective inhibition of l kappaB alpha phosphorylation and HIV-1 LTR-directed gene expression by novel antioxidant compounds Virology 234 1997 277 290
84. D.K. Kaul, R. Kollander, H. Mahaseth, and et al. Robust vascular protective effect of hydroxamic acid derivatives in a sickle mouse model of inflammation Microcirculation 13 2006 489 497
85. A. Di Gennaro, and J.Z. Haeggstrom Targeting leukotriene B4 in inflammation Expert Opin Ther Targets 18 2014 79 93
86. O. Radmark, and B. Samuelsson 5-Lipoxygenase: mechanisms of regulation J Lipid Res 50 suppl 2009 S40 S45
87. B. Samuelsson Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation Science 220 1983 568 575
88. V. Capra, G.E. Rovati, P. Mangano, C. Buccellati, R.C. Murphy, and A. Sala Transcellular biosynthesis of eicosanoid lipid mediators Biochim Biophys Acta 1851 2015 377 382
89. N. Patel, C.S. Gonsalves, M. Yang, P. Malik, and V.K. Kalra Placenta growth factor induces 5-lipoxygenase-activating protein to increase leukotriene formation in sickle cell disease Blood 113 2009 1129 1138
90. E.C. Vendramini, E.O. Vianna, I. De Lucena Angulo, F.B. De Castro, J.A. Martinez, and J. Terra-Filho Lung function and airway hyperresponsiveness in adult patients with sickle cell disease Am J Med Sci 332 2006 68 72
91. J.M. Knight-Madden, T.S. Forrester, N.A. Lewis, and A. Greenough Asthma in children with sickle cell disease and its association with acute chest syndrome Thorax 60 2005 206 210
92. J.J. Field, and M.R. DeBaun Asthma and sickle cell disease: two distinct diseases or part of the same process? Hematology Am Soc Hematol Educ Program 2009 45 53
93. W. Tian, X. Jiang, Y.K. Sung, J. Qian, K. Yuan, and M.R. Nicolls Leukotrienes in pulmonary arterial hypertension Immunol Res 58 2014 387 393
94. M. Newaskar, K.A. Hardy, and C.R. Morris Asthma in sickle cell disease ScientificWorldJournal 11 2011 1138 1152
95. C.C. Hoppe Inflammatory mediators of endothelial injury in sickle cell disease Hematol Oncol Clin North Am 28 2014 265 286
96. E. Duah, R.K. Adapala, N. Al-Azzam, and et al. Cysteinyl leukotrienes regulate endothelial cell inflammatory and proliferative signals through CysLT(2) and CysLT(1) receptors Sci Rep 3 2013 3274
97. B.N. Setty, and M.J. Stuart Eicosanoids in sickle cell disease: potential relevance of neutrophil leukotriene B4 to disease pathophysiology J Lab Clin Med 139 2002 80 89
98. P.M. O'Byrne Leukotrienes in the pathogenesis of asthma Chest 111 2 suppl 1997 27s 34s
99. Z.J. Wang, D.J. Wilkie, and R. Molokie Neurobiological mechanisms of pain in sickle cell disease Hematology Am Soc Hematol Educ Program 2010 2010 403 408
100. J.J. Field, R.C. Strunk, J.E. Knight-Perry, M.A. Blinder, R.R. Townsend, and M.R. DeBaun Urinary cysteinyl leukotriene E4 significantly increases during pain in children and adults with sickle cell disease Am J Hematol 84 2009 231 233
101. J.J. Field, J. Krings, N.L. White, and et al. Urinary cysteinyl leukotriene E(4) is associated with increased risk for pain and acute chest syndrome in adults with sickle cell disease Am J Hematol 84 2009 158 160
102. J.E. Jennings, T. Ramkumar, J. Mao, and et al. Elevated urinary leukotriene E4 levels are associated with hospitalization for pain in children with sickle cell disease Am J Hematol 83 2008 640 643
103. T. Lammermann, P.V. Afonso, B.R. Angermann, and et al. Neutrophil swarms require LTB4 and integrins at sites of cell death in vivo Nature 498 2013 371 375
104. P.V. Afonso, M. Janka-Junttila, Y.J. Lee, and et al. LTB4 is a signal-relay molecule during neutrophil chemotaxis Dev Cell 22 2012 1079 1091
105. J. Haynes Jr., and B. Obiako Activated polymorphonuclear cells increase sickle red blood cell retention in lung: role of phospholipids Am J Physiol Heart Circ Physiol 282 2002 H122 H130
106. M.A. Leong, C. Dampier, L. Varlotta, and J.L. Allen Airway hyperreactivity in children with sickle cell disease J Pediatr 131 1997 278 283
107. A.G. Palma-Carlos, M.L. Palma-Carlos, and A.C. Costa "Minor" hemoglobinopathies: a risk factor for asthma Eur Ann Allergy Clin Immunol 37 2005 177 182
108. M. Opene, J. Kurantsin-Mills, S. Husain, and B.O. Ibe Sickle erythrocytes and platelets augment lung leukotriene synthesis with downregulation of anti-inflammatory proteins: relevance in the pathology of the acute chest syndrome Pulm Circ 4 2014 482 495
109. C. Pergola, J. Gerstmeier, B. Monch, and et al. The novel benzimidazole derivative BRP-7 inhibits leukotriene biosynthesis in vitro and in vivo by targeting 5-lipoxygenase-activating protein (FLAP) Br J Pharmacol 171 2014 3051 3064
110. A.P. Sampson FLAP inhibitors for the treatment of inflammatory diseases Curr Opin Investig Drugs 10 2009 1163 1172
111. J. Haynes Jr., B.S. Baliga, B. Obiako, S. Ofori-Acquah, and B. Pace Zileuton induces hemoglobin F synthesis in erythroid progenitors: role of the L-arginine-nitric oxide signaling pathway Blood 103 2004 3945 3950
112. S. Kuvibidila, B.S. Baliga, R. Gardner, and et al. Differential effects of hydroxyurea and zileuton on interleukin-13 secretion by activated murine spleen cells: implication on the expression of vascular cell adhesion molecule-1 and vasoocclusion in sickle cell anemia Cytokine 30 2005 213 218
113. J.S. Dahlin, and J. Hallgren Mast cell progenitors: origin, development and migration to tissues Mol Immunol 63 2015 9 17
114. X. Qi, J. Hong, L. Chaves, and et al. Antagonistic regulation by the transcription factors C/EBPalpha and MITF specifies basophil and mast cell fates Immunity 39 2013 97 110
115. D.N. Xanthos, S. Gaderer, R. Drdla, and et al. Central nervous system mast cells in peripheral inflammatory nociception Mol Pain 7 2011 42
116. D. Levy, R. Burstein, V. Kainz, M. Jakubowski, and A.M. Strassman Mast cell degranulation activates a pain pathway underlying migraine headache Pain 130 2007 166 176
117. T.C. Theoharides, J. Donelan, K. Kandere-Grzybowska, and A. Konstantinidou The role of mast cells in migraine pathophysiology Brain Res Brain Res Rev 49 2005 65 76
118. J.J. Rozniecki, V. Dimitriadou, M. Lambracht-Hall, X. Pang, and T.C. Theoharides Morphological and functional demonstration of rat dura mater mast cell-neuron interactions in vitro and in vivo Brain Res 849 1999 1 15
119. M.M. Dowling, M.J. Noetzel, M.J. Rodeghier, and et al. Headache and migraine in children with sickle cell disease are associated with lower hemoglobin and higher pain event rates but not silent cerebral infarction J Pediatr 164 2014 1175 1180.e1
120. A.E. Niebanck, A.N. Pollock, K. Smith-Whitley, and et al. Headache in children with sickle cell disease: prevalence and associated factors J Pediatr 151 2007 67 72.e1
121. L.L. Reber, R. Sibilano, K. Mukai, and S.J. Galli Potential effector and immunoregulatory functions of mast cells in mucosal immunity Mucosal Immunol 8 2015 444 463
122. S.J. Galli, S. Nakae, and M. Tsai Mast cells in the development of adaptive immune responses Nat Immunol 6 2005 135 142
123. D. Roosterman, T. Goerge, S.W. Schneider, N.W. Bunnett, and M. Steinhoff Neuronal control of skin function: the skin as a neuroimmunoendocrine organ Physiol Rev 86 2006 1309 1379
124. B.K. Wershil, M. Tsai, E.N. Geissler, K.M. Zsebo, and S.J. Galli The rat c-kit ligand, stem cell factor, induces c-kit receptor-dependent mouse mast cell activation in vivo. Evidence that signaling through the c-kit receptor can induce expression of cellular function J Exp Med 175 1992 245 255
125. Y. Okayama, and T. Kawakami Development, migration, and survival of mast cells Immunol Res 34 2006 97 115
126. N. Vergnolle, J.L. Wallace, N.W. Bunnett, and M.D. Hollenberg Protease-activated receptors in inflammation, neuronal signaling and pain Trends Pharmacol Sci 22 2001 146 152
127. L. Vincent, D. Vang, J. Nguyen, and et al. Mast cell activation contributes to sickle cell pathobiology and pain in mice Blood 122 2013 1853 1862
128. C.A. Hillery, P.C. Kerstein, D. Vilceanu, and et al. Transient receptor potential vanilloid 1 mediates pain in mice with severe sickle cell disease Blood 118 2011 3376 3383
129. T.C. Theoharides, K.D. Alysandratos, A. Angelidou, and et al. Mast cells and inflammation Biochim Biophys Acta 1822 2012 21 33
130. B.J. Davis, B.F. Flanagan, A.M. Gilfillan, D.D. Metcalfe, and J.W. Coleman Nitric oxide inhibits IgE-dependent cytokine production and Fos and Jun activation in mast cells J Immunol 173 2004 6914 6920
131. W. Zhao, S. Zhou, W. Yao, and et al. Propofol prevents lung injury after intestinal ischemia-reperfusion by inhibiting the interaction between mast cell activation and oxidative stress Life Sci 108 2014 80 87
132. W. Zhao, X. Gan, G. Su, and et al. The interaction between oxidative stress and mast cell activation plays a role in acute lung injuries induced by intestinal ischemia-reperfusion J Surg Res 187 2014 542 552
133. R. Saluja, I. Delin, G.P. Nilsson, and M. Adner FcepsilonR1-mediated mast cell reactivity is amplified through prolonged toll-like receptor-ligand treatment PLoS One 7 2012 e43547
134. H. Qiao, M.V. Andrade, F.A. Lisboa, K. Morgan, and M.A. Beaven FcepsilonR1 and toll-like receptors mediate synergistic signals to markedly augment production of inflammatory cytokines in murine mast cells Blood 107 2006 610 618
135. L.A. Michaels, K. Ohene-Frempong, H. Zhao, and S.D. Douglas Serum levels of substance P are elevated in patients with sickle cell disease and increase further during vaso-occlusive crisis Blood 92 1998 3148 3151
136. L.B. Afrin Mast cell activation syndrome as a significant comorbidity in sickle cell disease Am J Med Sci 348 2014 460 464
137. A.B. Fall, M. Toppet, A. Ferster, P. Fondu, R. Vanhaelen-Fastre, and M. Vanhaelen In vitro antisickling activity of cromolyn sodium Br J Haematol 103 1998 957 959
138. M. Toppet, A.B. Fall, A. Ferster, and et al. Antisickling activity of sodium cromoglicate in sickle-cell disease Lancet 356 2000 309
139. M. Karimi, O.R. Zekavat, S. Sharifzadeh, and K. Mousavizadeh Clinical response of patients with sickle cell anemia to cromolyn sodium nasal spray Am J Hematol 81 2006 809 816
140. K.L. Wallace, M.A. Marshall, S.I. Ramos, and et al. NKT cells mediate pulmonary inflammation and dysfunction in murine sickle cell disease through production of IFN-γ and CXCR3 chemokines Blood 114 2009 667 676
141. A. Bendelac, P.B. Savage, and L. Teyton The biology of NKT cells Annu Rev Immunol 25 2007 297 336
142. G.R. Milne, and T.M. Palmer Anti-inflammatory and immunosuppressive effects of the A2A adenosine receptor ScientificWorldJournal 11 2011 320 339
143. G. Lin, J.J. Field, J.C. Yu, and et al. NF-kappaB is activated in CD4+ iNKT cells by sickle cell disease and mediates rapid induction of adenosine A2A receptors PLoS One 8 2013 e74664
144. A.K. Stanic, J.S. Bezbradica, J.J. Park, L. Van Kaer, M.R. Boothby, and S. Joyce Cutting edge: the ontogeny and function of Va14Ja18 natural T lymphocytes require signal processing by protein kinase C theta and NF-kappa B J Immunol 172 2004 4667 4671
145. J.L. Matsuda, T. Mallevaey, J. Scott-Browne, and L. Gapin CD1d-restricted iNKT cells, the 'Swiss-Army knife' of the immune system Curr Opin Immunol 20 2008 358 368
146. V. Kumar NKT-cell subsets: promoters and protectors in inflammatory liver disease J Hepatol 59 2013 618 620
147. J.R. Groom, and A.D. Luster CXCR3 ligands: redundant, collaborative and antagonistic functions Immunol Cell Biol 89 2011 207 215
148. L.J. Murphree, G.W. Sullivan, M.A. Marshall, and J. Linden Lipopolysaccharide rapidly modifies adenosine receptor transcripts in murine and human macrophages: role of NF-kappaB in A(2A) adenosine receptor induction Biochem J 391 Pt 3 2005 575 580
149. A. Ohta, and M. Sitkovsky Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage Nature 414 2001 916 920
150. C.M. Lappas, Y.J. Day, M.A. Marshall, V.H. Engelhard, and J. Linden Adenosine A2A receptor activation reduces hepatic ischemia reperfusion injury by inhibiting CD1d-dependent NKT cell activation J Exp Med 203 2006 2639 2648
151. L. Li, L. Huang, S.S. Sung, and et al. NKT cell activation mediates neutrophil IFN-gamma production and renal ischemia-reperfusion injury J Immunol 178 2007 5899 5911
152. A. Thedrez, C. de Lalla, S. Allain, and et al. CD4 engagement by CD1d potentiates activation of CD4+ invariant NKT cells2007 Blood 110 2007 251 258
153. J.F. Chen, H.K. Eltzschig, and B.B. Fredholm Adenosine receptors as drug targets - what are the challenges? Nat Rev Drug Discov 12 2013 265 286
154. K.A. Jacobson, and Z.G. Gao Adenosine receptors as therapeutic targets Nat Rev Drug Discov 5 2006 247 264
155. J.J. Field, D.G. Nathan, and J. Linden The role of adenosine signaling in sickle cell therapeutics Hematol Oncol Clin North Am 28 2014 287 299
156. S. Ryzhov, A.E. Goldstein, A. Matafonov, D. Zeng, I. Biaggioni, and I. Feoktistov Adenosine-activated mast cells induce IgE synthesis by B lymphocytes: an A2B-mediated process involving Th2 cytokines IL-4 and IL-13 with implications for asthma J Immunol 172 2004 7726 7733
157. T. Mi, S. Abbasi, H. Zhang, and et al. Excess adenosine in murine penile erectile tissues contributes to priapism via A2B adenosine receptor signaling J Clin Invest 118 2008 1491 1501
158. J. Wen, X. Jiang, Y. Dai, and et al. Increased adenosine contributes to penile fibrosis, a dangerous feature of priapism, via A2B adenosine receptor signaling FASEB J 24 2010 740 749
159. Y. Zhang, Y. Dai, J. Wen, and et al. Detrimental effects of adenosine signaling in sickle cell disease Nat Med 17 2011 79 86
160. E. Alchera, L. Tacchini, C. Imarisio, and et al. Adenosine-dependent activation of hypoxia-inducible factor-1 induces late preconditioning in liver cells Hepatology 48 2008 230 239
161. Z. Ben-Ari, O. Pappo, J. Sulkes, Y. Cheporko, B.A. Vidne, and E. Hochhauser Effect of adenosine A2A receptor agonist (CGS) on ischemia/reperfusion injury in isolated rat liver Apoptosis 10 2005 955 962
162. M.D. Okusa, J. Linden, T. Macdonald, and L. Huang Selective A2A adenosine receptor activation reduces ischemia-reperfusion injury in rat kidney Am J Physiol 277 3 Pt 2 1999 F404 F412
163. S.M. Peirce, T.C. Skalak, J.M. Rieger, T.L. Macdonald, and J. Linden Selective A(2A) adenosine receptor activation reduces skin pressure ulcer formation and inflammation Am J Physiol Heart Circ Physiol 281 2001 H67 H74
164. L.M. Gazoni, V.E. Laubach, D.P. Mulloy, and et al. Additive protection against lung ischemia-reperfusion injury by adenosine A2A receptor activation before procurement and during reperfusion J Thorac Cardiovasc Surg 135 2008 156 165
165. Y. Zhai, X.D. Shen, W.W. Hancock, and et al. CXCR3+CD4+ T cells mediate innate immune function in the pathophysiology of liver ischemia/reperfusion injury J Immunol 176 2006 6313 6322
166. Z. Yang, Y.J. Day, M.C. Toufektsian, and et al. Myocardial infarct-sparing effect of adenosine A2A receptor activation is due to its action on CD4+ T lymphocytes Circulation 114 2006 2056 2064
167. J. Reutershan, R.E. Cagnina, D. Chang, J. Linden, and K. Ley Therapeutic anti-inflammatory effects of myeloid cell adenosine receptor A2a stimulation in lipopolysaccharide-induced lung injury J Immunol 179 2007 1254 1263
168. K.L. Wallace, and J. Linden Adenosine A2A receptors induced on iNKT and NK cells reduce pulmonary inflammation and injury in mice with sickle cell disease Blood 116 2010 5010 5020
169. D.G. Nathan, J. Field, G. Lin, and et al. Sickle cell disease (SCD), iNKT cells, and regadenoson infusion Trans Am Clin Climatol Assoc 123 2012 312 317 discussion 7-8
170. J.J. Field, G. Lin, M.M. Okam, and et al. Sickle cell vaso-occlusion causes activation of iNKT cells that is decreased by the adenosine A2A receptor agonist regadenoson Blood 121 2013 3329 3334
171. S. Charache, M.L. Terrin, R.D. Moore, and et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia N Engl J Med 332 1995 1317 1322
172. M.H. Steinberg, W.F. McCarthy, O. Castro, and et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up Am J Hematol 85 2010 403 408
173. R.M. Bookchin, R.L. Nagel, and T. Balazs Role of hybrid tetramer formation in gelation of haemoglobin S Nature 256 1975 667 668
174. S.F. Ofori-Acquah, B.N. Green, S.C. Davies, K.H. Nicolaides, G.R. Serjeant, and D.M. Layton Mass spectral analysis of asymmetric hemoglobin hybrids: demonstration of Hb FS (alpha2gammabetaS) in sickle cell disease Anal Biochem 298 2001 76 82
175. M. Tsai, A. Kita, J. Leach, and et al. In vitro modeling of the microvascular occlusion and thrombosis that occur in hematologic diseases using microfluidic technology J Clin Invest 122 2012 408 418
176. B.P. Yawn, G.R. Buchanan, A.N. Afenyi-Annan, and et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members JAMA 312 2014 1033 1048
177. A.A. Canalli, R.F. Proenca, C.F. Franco-Penteado, and et al. Participation of Mac-1, LFA-1 and VLA-4 integrins in the in vitro adhesion of sickle cell disease neutrophils to endothelial layers, and reversal of adhesion by simvastatin Haematologica 96 2011 526 533
178. A.A. Canalli, C.F. Franco-Penteado, F. Traina, S.T.O. Saad, F.F. Costa, and N. Conran Role for cAMP-protein kinase A signalling in augmented neutrophil adhesion and chemotaxis in sickle cell disease Eur J Haematol 79 2007 330 337
179. N. Conran, C.B. Almeida, C. Lanaro, and et al. Inhibition of caspase-dependent spontaneous apoptosis via a cAMP-protein kinase A dependent pathway in neutrophils from sickle cell disease patients Br J Haematol 139 2007 148 158
180. J. Davila, D. Manwani, L. Vasovic, and et al. A novel inflammatory role for platelets in sickle cell disease Platelets 30 2014 1 4
181. A. Turhan, L.A. Weiss, N. Mohandas, B.S. Coller, and P.S. Frenette Primary role for adherent leukocytes in sickle cell vascular occlusion: a new paradigm Proc Natl Acad Sci U S A 99 2002 3047 3051
182. J. Haynes Jr., B. Obiako, J.A. King, R.B. Hester, and S. Ofori-Acquah Activated neutrophil-mediated sickle red blood cell adhesion to lung vascular endothelium: role of phosphatidylserine-exposed sickle red blood cells Am J Physiol Heart Circ Physiol 291 2006 H1679 H1685
183. J. Haynes Jr., B. Obiako, R.B. Hester, B.S. Baliga, and T. Stevens Hydroxyurea attenuates activated neutrophil-mediated sickle erythrocyte membrane phosphatidylserine exposure and adhesion to pulmonary vascular endothelium Am J Physiol Heart Circ Physiol 294 2008 H379 H385
184. F.R. Pallis, N. Conran, K.Y. Fertrin, S.T. Olalla Saad, F.F. Costa, and C.F. Franco-Penteado Hydroxycarbamide reduces eosinophil adhesion and degranulation in sickle cell anaemia patients Br J Haematol 164 2014 286 295
185. H. Elmariah, M.E. Garrett, L.M. De Castro, and et al. Factors associated with survival in a contemporary adult sickle cell disease cohort Am J Hematol 89 2014 530 535
186. J.S. Mohan, G.Y. Lip, J. Wright, D. Bareford, and A.D. Blann Plasma levels of tissue factor and soluble E-selectin in sickle cell disease: relationship to genotype and to inflammation Blood Coagul Fibrinolysis 16 2005 209 214
187. I. Okpala Leukocyte adhesion and the pathophysiology of sickle cell disease Curr Opin Hematol 13 2006 40 44
188. A. Solovey, Y. Lin, P. Browne, S. Choong, E. Wayner, and R.P. Hebbel Circulating activated endothelial cells in sickle cell anemia N Engl J Med 337 1997 1584 1590
189. D. Manwani, and P.S. Frenette Vaso-occlusion in sickle cell disease: pathophysiology and novel targeted therapies Blood 122 2013 3892 3898
190. S. Laurance, P. Lansiaux, F.X. Pellay, and et al. Differential modulation of adhesion molecule expression by hydroxycarbamide in human endothelial cells from the micro- and macrocirculation: potential implications in sickle cell disease vasoocclusive events Haematologica 96 2011 534 542
191. M. Brun, S. Bourdoulous, P.O. Couraud, J. Elion, R. Krishnamoorthy, and C. Lapoumeroulie Hydroxyurea downregulates endothelin-1 gene expression and upregulates ICAM-1 gene expression in cultured human endothelial cells Pharmacogenomics J 3 2003 215 226
192. J.D. Lebensburger, T. Howard, Y. Hu, and et al. Hydroxyurea therapy of a murine model of sickle cell anemia inhibits the progression of pneumococcal disease by down-modulating E-selectin Blood 119 2012 1915 1921
193. A.S. Bowers, H.L. Reid, A. Greenidge, C. Landis, and M. Reid Blood viscosity and the expression of inflammatory and adhesion markers in homozygous sickle cell disease subjects with chronic leg ulcers PLoS One 8 2013 e68929
194. S.B. Ferreira, L.C. de Brito, M.P. Oliveira, and et al. Periapical cytokine expression in sickle cell disease J Endod 41 2015 358 362
195. X. Niu, M. Nouraie, A. Campbell, and et al. Angiogenic and inflammatory markers of cardiopulmonary changes in children and adolescents with sickle cell disease PLoS One 4 2009 e7956
196. B.O. Musa, G.C. Onyemelukwe, J.O. Hambolu, A.I. Mamman, and A.H. Isa Pattern of serum cytokine expression and T-cell subsets in sickle cell disease patients in vaso-occlusive crisis Clin Vaccine Immunol 17 2010 602 608
197. C. Lanaro, C.F. Franco-Penteado, D.M. Albuqueque, S.T.O. Saad, N. Conran, and F.F. Costa Altered levels of cytokines and inflammatory mediators in plasma and leukocytes of sickle cell anemia patients and effects of hydroxyurea therapy J Leukoc Biol 85 2009 235 242
198. S. Sarray, L.R. Saleh, F. Lisa Saldanha, H.H. Al-Habboubi, N. Mahdi, and W.Y. Almawi Serum IL-6, IL-10, and TNFalpha levels in pediatric sickle cell disease patients during vasoocclusive crisis and steady state condition Cytokine 72 2015 43 47
199. B. Keikhaei, A.R. Mohseni, R. Norouzirad, and et al. Altered levels of pro-inflammatory cytokines in sickle cell disease patients during vaso-occlusive crises and the steady state condition Eur Cytokine Netw 24 2013 45 52
200. G.M. Vercellotti, and J.D. Belcher Not simply misshapen red cells: multimolecular and cellular events in sickle vaso-occlusion J Clin Invest 124 2014 1462 1465
201. E.M. Finnegan, A. Turhan, D.E. Golan, and G.A. Barabino Adherent leukocytes capture sickle erythrocytes in an in vitro flow model of vaso-occlusion Am J Hematol 82 2007 266 275
202. Z. Novakova, S. Hubackova, M. Kosar, and et al. Cytokine expression and signaling in drug-induced cellular senescence Oncogene 29 2010 273 284
203. T.S. Lee, and L.Y. Chau Heme oxygenase-1 mediates the anti-inflammatory effect of interleukin-10 in mice Nat Med 8 2002 240 246
204. O.A. Adisa, Y. Hu, S. Ghosh, D. Aryee, I. Osunkwo, and S.F. Ofori-Acquah Association between plasma free haem and incidence of vaso-occlusive episodes and acute chest syndrome in children with sickle cell disease Br J Haematol 162 2013 702 705
205. R. Camehn, and K. Rehse New NO donors with antithrombotic and vasodilating activities, Part 28. N-(1-cyanoalkyl)-N-hydroxyureas Arch Pharm 333 2000 27 31
206. J. Huang, S.B. Hadimani, J.W. Rupon, S.K. Ballas, D.B. Kim-Shapiro, and S.B. King Iron nitrosyl hemoglobin formation from the reactions of hemoglobin and hydroxyurea Biochemistry 41 2002 2466 2474
207. M.T. Gladwin, J.H. Shelhamer, F.P. Ognibene, and et al. Nitric oxide donor properties of hydroxyurea in patients with sickle cell disease Br J Haematol 116 2002 436 444
208. V.P. Cokic, S.A. Andric, S.S. Stojilkovic, C.T. Noguchi, and A.N. Schechter Hydroxyurea nitrosylates and activates soluble guanylyl cyclase in human erythroid cells Blood 111 2008 1117 1123
209. C.B. Almeida, L.E. Souza, F.C. Leonardo, and et al. Acute hemolytic vascular inflammatory processes are prevented by nitric oxide replacement or a single dose of hydroxyurea Blood 126 2015 711 720